This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesTrendsBuy This Stock JUNS vs. NLTX, TELO, VIRI, ANIX, XCUR, PLRX, BMEA, THTX, GNLX, and AVTEShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Neoleukin Therapeutics (NLTX), Telomir Pharmaceuticals (TELO), Virios Therapeutics (VIRI), Anixa Biosciences (ANIX), Exicure (XCUR), Pliant Therapeutics (PLRX), Biomea Fusion (BMEA), Theratechnologies (THTX), Genelux (GNLX), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical preparations" industry. Jupiter Neurosciences vs. Neoleukin Therapeutics Telomir Pharmaceuticals Virios Therapeutics Anixa Biosciences Exicure Pliant Therapeutics Biomea Fusion Theratechnologies Genelux Aerovate Therapeutics Jupiter Neurosciences (NASDAQ:JUNS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking. Does the MarketBeat Community believe in JUNS or NLTX? Neoleukin Therapeutics received 49 more outperform votes than Jupiter Neurosciences when rated by MarketBeat users. However, 100.00% of users gave Jupiter Neurosciences an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformJupiter NeurosciencesOutperform Votes1100.00% Underperform VotesNo VotesNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Which has preferable earnings and valuation, JUNS or NLTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJupiter NeurosciencesN/AN/AN/AN/AN/ANeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-3.69 Is JUNS or NLTX more profitable? Jupiter Neurosciences' return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jupiter NeurosciencesN/A N/A N/A Neoleukin Therapeutics N/A -37.22%-30.91% Does the media prefer JUNS or NLTX? In the previous week, Jupiter Neurosciences' average media sentiment score of 0.94 beat Neoleukin Therapeutics' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Jupiter Neurosciences Positive Neoleukin Therapeutics Neutral Do analysts rate JUNS or NLTX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of JUNS or NLTX? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryJupiter Neurosciences beats Neoleukin Therapeutics on 6 of the 9 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.52M$6.45B$5.31B$7.34BDividend YieldN/A3.21%5.45%4.35%P/E RatioN/A6.9221.9417.81Price / SalesN/A231.01380.6697.70Price / CashN/A65.6738.2534.62Price / BookN/A5.936.453.98Net IncomeN/A$143.22M$3.22B$247.75M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$0.62-12.3%N/AN/A$20.52MN/A0.005Gap DownNLTXNeoleukin TherapeuticsN/A$8.79-9.1%N/A-62.3%$82.61MN/A-2.8390High Trading VolumeTELOTelomir Pharmaceuticals1.3866 of 5 stars$2.77-5.5%$15.00+441.5%-68.9%$82.44MN/A-4.781VIRIVirios Therapeutics0.3682 of 5 stars$4.25+1.7%$3.00-29.4%+880.5%$81.85MN/A-15.745News CoverageANIXAnixa Biosciences2.4601 of 5 stars$2.49-1.6%$9.00+261.4%-12.8%$80.17M$210,000.00-6.385Gap DownXCURExicure2.0344 of 5 stars$12.48-4.0%N/A+1,404.5%$78.82M$500,000.00-6.0350Short Interest ↓Gap UpPLRXPliant Therapeutics4.0861 of 5 stars$1.25-6.7%$13.31+965.0%-88.3%$76.55M$1.58M-0.3790Gap DownBMEABiomea Fusion1.963 of 5 stars$2.01-5.2%$23.91+1,089.5%-84.5%$75.52MN/A-0.5050THTXTheratechnologiesN/A$1.64+10.8%N/A+85.3%$75.41M$85.87M-16.40140GNLXGenelux0.79 of 5 stars$2.16-9.6%$18.25+744.9%-36.3%$74.75M$8,000.00-2.2710AVTEAerovate Therapeutics0.7987 of 5 stars$2.52+1.2%$2.25-10.7%-87.5%$73.04MN/A-0.8420Positive News Related Companies and Tools Related Companies NLTX Competitors TELO Competitors VIRI Competitors ANIX Competitors XCUR Competitors PLRX Competitors BMEA Competitors THTX Competitors GNLX Competitors AVTE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JUNS Stock Free JUNS Stock Alerts